Results 51 to 60 of about 5,422 (196)

Emerging drugs for Cushing's disease [PDF]

, 2015
INTRODUCTION: Considering the effects of uncontrolled hypercortisolism on morbidity and mortality, there is a clear need for effective medical therapy for patients with Cushing's disease (CD).
Grossman, AB, Guelho, DL
core   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics

Frontiers in Endocrinology
BackgroundAdrenocortical carcinoma (ACC) is an aggressive endocrine malignancy with limited therapeutic options. Treating advanced ACC with mitotane, the cornerstone therapy, remains challenging, thus underscoring the significance to predict mitotane ...
Jie Zhang, Luming Wu, Tingwei Su, Haoyu Liu, Lei Jiang, Yiran Jiang, Zhiyuan Wu, Lu Chen, Haorong Li, Jie Zheng, Yingkai Sun, Hangya Peng, Rulai Han, Guang Ning, Lei Ye, Weiqing Wang   +15 more
doaj   +1 more source

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma

IJU Case Reports, 2023
Introduction Advanced adrenocortical carcinoma has a poor prognosis and is treated with chemotherapy that includes mitotane with etoposide, doxorubicin, and cisplatin as first‐line therapy.
Masaya Senda, Kohei Hashimoto, Tetsuya Shindo, Ko Kobayashi, Toshiaki Tanaka, Naoya Masumori   +5 more
doaj   +1 more source

IGF-I influences everolimus activity in medullary thyroid carcinoma [PDF]

, 2015
Context: Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid parafollicular C cells. It has been previously demonstrated that insulin-like growth factor I (IGF-I) protects MTC from the effects of antiproliferative drugs. Everolimus,
degli Uberti, Ettore C., Di Pasquale, Carmelina, Gagliano, Teresa, GENTILIN, ERICA, MERANTE BOSCHIN, ISABELLA, Pelizzo, Mariarosa, Rossi, Martina, Rossi, Roberta, Tagliati, Federico, Zatelli, Maria Chiara   +9 more
core   +1 more source

Role of Palliative Bronchial Stenting in Endobronchial Metastasis: An Atypical Case of Metastatic Adrenocortical Carcinoma in a Young Patient

Clinical Case Reports, Volume 13, Issue 10, October 2025.
Sequential bronchoscopic management of left main bronchus endobronchial metastasis. (A–B) Obstructive lesion visualized. (C) Post‐debulking lumen restored. (D) A 10×30 mm fully covered self‐expanding metal stent placed to maintain airway patency, resulting in improved ventilation and symptom relief.
Sushrut Ingawale, Nuthan Bhat, Rahul Kothari, Shivaji Karki, Abhiroop Verma   +4 more
wiley   +1 more source

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane

Clinical Medicine Insights: Oncology, 2021
Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Treatment options for ACC are limited, with resection the main intervention. Most cases present in late metastatic cases, and data regarding effective therapies is limited.
Walid Alam, Youssef Bouferraa, Yolla Haibe, Ali Shamseddine   +3 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-940, June 2025.
Cancer Science, Volume 117, Issue S1, Page 1-2148, January 2026.
wiley   +2 more sources

The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells

Cancer Cell International, 2018
Background New drugs for adrenocortical carcinoma (ACC) are needed because most patients undergo rapid disease progression despite surgery and adjuvant therapy with mitotane.
Elaine Silveira, Isadora Pontes Cavalcante, Jean Lucas Kremer, Pedro Omori Ribeiro de Mendonça, Claudimara Ferini Pacicco Lotfi   +4 more
doaj   +1 more source

Feminizing adrenocortical carcinoma with distant metastases: can surgery be considered? [PDF]

, 2014
Functioning adrenocortical carcinomas are rare diseases with dismal prognosis. A 41-yearold man presenting with gynecomastia had a giant feminizing adrenocortical carcinoma at stage IV.
Fancellu, Alessandro, Pinna, Antonio <1963- >, Porcu, Alberto   +2 more
core   +3 more sources